Melanoma Stage IV Clinical Trials

25 recruitingLast updated: June 17, 2026

There are 25 actively recruiting melanoma stage iv clinical trials across 12 countries. Studies span Phase 2, Phase 1, Not Applicable, Early Phase 1. Top locations include Pittsburgh, Pennsylvania, United States, Tampa, Florida, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Melanoma Stage IV Trials at a Glance

25 actively recruiting trials for melanoma stage iv are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Pittsburgh, Tampa, and New York. Lead sponsors running melanoma stage iv studies include H. Lee Moffitt Cancer Center and Research Institute, Georgiamune Inc, and Erasmus Medical Center.

Browse melanoma stage iv trials by phase

Treatments under study

About Melanoma Stage IV Clinical Trials

Looking for clinical trials for Melanoma Stage IV? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Melanoma Stage IV trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Melanoma Stage IV clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 1Phase 2

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Metastatic MelanomaMelanoma Stage IVMelanoma Stage III+1 more
Perspective Therapeutics300 enrolled13 locationsNCT05655312
Recruiting

Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy

Melanoma Stage IV
Medical University of Graz50 enrolled1 locationNCT07635732
Recruiting
Phase 2

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Cutaneous MelanomaMelanoma Stage IVMucosal Melanoma
University Health Network, Toronto54 enrolled1 locationNCT06319196
Recruiting
Phase 2

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Melanoma Stage IVMelanoma Stage III
University of California, San Francisco25 enrolled2 locationsNCT04598009
Recruiting
Phase 1

A Study of VET3-TGI in Patients With Solid Tumors

Cervical CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+10 more
KaliVir Immunotherapeutics60 enrolled7 locationsNCT06444815
Recruiting
Phase 2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Melanoma Stage IVInoperable DiseaseMelanoma Stage III
H. Lee Moffitt Cancer Center and Research Institute29 enrolled1 locationNCT04562129
Recruiting
Phase 2

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

MelanomaAdvanced MelanomaMelanoma Stage IV+1 more
H. Lee Moffitt Cancer Center and Research Institute90 enrolled1 locationNCT06295159
Recruiting
Phase 1Phase 2

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Solid TumorMelanoma Stage IV
Georgiamune Inc117 enrolled11 locationsNCT06425926
Recruiting
Phase 2

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

MelanomaMelanoma Stage IVMelanoma (Skin)+1 more
University of California, Irvine14 enrolled1 locationNCT06771544
Recruiting
Early Phase 1

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IVBRAF V600 MutationMelanoma Stage III
H. Lee Moffitt Cancer Center and Research Institute50 enrolled1 locationNCT04741997
Recruiting
Phase 2

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Melanoma Stage IV
Melanoma Institute Australia218 enrolled9 locationsNCT03340129
Recruiting

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

MelanomaUnresectable MelanomaMelanoma Stage IV+1 more
University of Wisconsin, Madison24 enrolled1 locationNCT06199713
Recruiting
Not Applicable

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Melanoma Stage IVPediatric ALLMelanoma Stage III+4 more
Miltenyi Biomedicine GmbH40 enrolled7 locationsNCT06508775
Recruiting
Not Applicable

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Melanoma Stage IVMelanoma Stage III
Kelly McMasters30 enrolled1 locationNCT04513028
Recruiting
Phase 2

[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

Malignant Melanoma Stage IV
Barbara Malene Fischer20 enrolled2 locationsNCT07215182
Recruiting
Phase 1Phase 2

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Triple-Negative Breast CancerNon-small Cell Lung CancerMetastatic Cancer+6 more
Hadassah Medical Organization3 enrolled1 locationNCT05296564
Recruiting
Phase 1

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

MelanomaMelanoma Stage IVMelanoma Stage III
Inge Marie Svane10 enrolled2 locationsNCT06204991
Recruiting
Phase 1Phase 2

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

CancerCutaneous MelanomaMelanoma Stage IV+1 more
Krystal Biotech, Inc.240 enrolled15 locationsNCT05970497
Recruiting

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

Advanced CancerMelanoma Stage IVMelanoma Stage III
Grupo Español Multidisciplinar de Melanoma400 enrolled39 locationsNCT03605771
Recruiting
Phase 1Phase 2

FMT to Convert Response to Immunotherapy

Melanoma Stage IVMelanoma Stage III
The Netherlands Cancer Institute24 enrolled1 locationNCT05251389